The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
Timothy F. Cloughesy
UCLA Neuro-Oncology Program
David Geffen School of Medicine at UCLA
University of California
Los Angeles
USA
Name/email consistency: high
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Cloughesy, T.F., Wen, P.Y., Robins, H.I., Chang, S.M., Groves, M.D., Fink, K.L., Junck, L., Schiff, D., Abrey, L., Gilbert, M.R., Lieberman, F., Kuhn, J., DeAngelis, L.M., Mehta, M., Raizer, J.J., Yung, W.K., Aldape, K., Wright, J., Lamborn, K.R., Prados, M.D. J. Clin. Oncol. (2006)
- Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Cloughesy, T.F., Kuhn, J., Robins, H.I., Abrey, L., Wen, P., Fink, K., Lieberman, F.S., Mehta, M., Chang, S., Yung, A., DeAngelis, L., Schiff, D., Junck, L., Groves, M., Paquette, S., Wright, J., Lamborn, K., Sebti, S.M., Prados, M. J. Clin. Oncol. (2005)
